Quantcast

Latest Coagulation system Stories

2014-08-26 23:05:43

Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, reports on the findings of a new study published in the Journal of Neurosurgery regarding the increased difficulties of stopping bleeding events for patients using certain direct Factor Xa inhibitor medications, including Xarelto®. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have suffered serious bleeding events after using Xarelto®....

2014-08-26 08:30:42

- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions - MISSISSAUGA, ON, Aug. 26, 2014 /CNW/ - Today Biogen Idec (NASDAQ: BIIB) announces that Health Canada has approved ELOCTATE(TM) [Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein] for the control and prevention of bleeding episodes and routine prophylaxis in adults and children aged 12 and older with hemophilia A.(1) ELOCTATE is...

2014-08-21 16:24:44

Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug. 21, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary...

2014-07-17 23:01:02

The Firm is actively investigating potential claims on behalf of patients who allegedly suffered Xarelto internal bleeding, strokes, pulmonary embolism and/or deep vein thrombosis following use of the blood thinner. New York, NY (PRWEB) July 17, 2014 Bernstein Liebhard LLP has launched a new website for individuals who may be eligible to file a Xarelto lawsuit (http://www.xareltolawsuitcenter.com/) alleging injuries caused by the new-generation blood thinner, the Firm reports. The site...

2014-07-16 08:27:31

SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this...

2014-07-07 16:23:47

First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven(®) RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative management in patients with Glanzmann's Thrombasthenia (GT) with refractoriness to...

2014-06-23 08:27:50

Phase 1 Clinical Data Highlights Factor IXa as an Excellent Target for Anticoagulation Therapy BASKING RIDGE, N.J., June 23, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the discovery and development of actively controllable aptamer therapeutics for the acute care setting, today announced the publication in the Journal of Thrombosis and Thrombolysis of data from a single escalating-dose Phase 1 clinical trial of the REG2...

2014-06-23 08:27:25

LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, have entered into a collaboration for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. "Bayer is a worldwide leader in the treatment of hemophilia A and we are highly committed to advancing innovative treatment options for...

2014-06-16 04:21:39

IMPACT Dx(TM) Combined Function System Will Also Be Available in the European Union SAN DIEGO, June 16, 2014 /PRNewswire/ -- Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., was notified today by Sequenom, Inc. that it received premarket clearance from the U.S. Food and Drug Administration (FDA) for the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx(TM) System. The IMPACT Dx(TM) Factor V Leiden and Factor II...

2014-06-11 08:32:01

LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coagulation Diagnostic Testing Marketshttp://www.reportbuyer.com/pharma_healthcare/diagnostics/coagulation_diagnostic_testing_markets_1.html Coagulation testing, which encompasses both laboratory and point of care (POC) testing, will continue to be one of the most important segments of the in vitro diagnostics market for the foreseeable future. Many of the new models of laboratory...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related